简体
简体中文
繁體中文

Lisata Therapeutics, Inc. LSTA

已收盘 02-06 16:00:00 美东时间

4.54

-0.060

-1.30%

华盛通华盛通
立即下载
  • 最 高4.655
  • 今 开4.62
  • 成交量 12.78万股
  • 最 低 4.54
  • 昨 收 4.60
  • 总市值 4004.61万
  • 52周最高 4.8918
  • 市盈率 --
  • 换手率 1.45%
  • 52周最低 1.81
  • 委 比 80.00%
  • 总股本 882.07万
  • 历史最高 1483.50
  • 量 比 1.04
  • 振 幅 2.50%
  • 历史最低 1.81
  • 每 手 1
  • 风险率 0.51%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Lisata Therapeutics ends Qilu certepetide collaboration deal

    Lisata Therapeutics ( ($LSTA) ) just unveiled an announcement. On January 23, 2...

    01-27 21:48

  • BUZZ-U.S. STOCKS ON THE MOVE-Oklo, AMD,  Lam Research

    BUZZ-U.S. STOCKS ON THE MOVE-Oklo, AMD,  Lam Research Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks staged a modest recovery on Wednesday after the sharpest equities se

    01-22 02:53

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

    Gainers PAVmed (NASDAQ:PAVM) stock increased by 250.7% to $21.71 during Wednes...

    01-22 01:05

  • Brookline Capital Downgrades Lisata Therapeutics to Hold

    Brookline Capital analyst Kemp Dolliver downgrades Lisata Therapeutics (NASDAQ:LSTA) from Buy to Hold.

    01-22 00:04

  • BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies

    BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks staged a modest recovery on Wednesday after the sharpest e

    01-21 23:49

  • Why Is Lisata Therapeutics Stock Gaining Today?

    Lisata Therapeutics shares surged premarket after Kuva Labs agreed to acquire the company for $4 per share in cash plus two milestone-based CVRs.

    01-21 23:31

  • Lisata Therapeutics To Be Acquired By Kuva Labs In $4.00/Share Tender Offer

    Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestonesOffer represents an approximate 85% premium over the most recent

    01-21 20:03

  • Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

    Lisata Therapeutics has entered into a binding term sheet to be acquired by Kuva Labs for $4.00 per share in cash, representing an 85% premium over its recent stock price. Shareholders will also receive two contingent value rights (CVRs) worth $1.00 each, contingent on certain milestones. The transaction, approved by both companies' boards, values Lisata's clinical pipeline and lead product certepetide, a novel anti-cancer therapy. Kuva plans to ...

    01-21 12:00

  • 12 Health Care Stocks Moving In Friday's After-Market Session

    Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...

    01-10 05:05

  • 电话会总结 | Lisata(LSTA)2025财年Q3业绩电话会核心要点

    <span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>&#8226; 根据Lisata Therapeutics 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **运营费用表现:** - 2025年第三季度运营费用为440万美元,较2024年同期的530万美元下降90万美元 - 研发费用为200万美元,较2024年同期的250万美元减少60万美元 - 一般管理费用为250万美元,较2024年同期的280万美元减少30万美元 - 净亏损为420万美元,较2024年同期的490万美元有所改善 **现金状况:** - 截至2025年第三季度末,现金及现金等价物为1900万美元 - 公司预计现有

    2025-11-10 12:01